NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$28.35 With US$31.37 ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) fell 6.1% during mid-day trading on Monday after the company announced weaker ...

Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE:BHVN – Free Report) by 4.4% in the 4th quarter, ...

Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained ...

Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

California Resources Corp.’s (CRC) shares plummeted 11.7% after posting fourth-quarter 2024 adjusted earnings per share of $0.91, missing the Zacks Consensus Estimate of $0.34. Shares of TG ...

Kansas City Life Insurance Company recorded a net loss of $12.6 million or $1.30 per share in the fourth quarter of 2024, down from net income of $49.1 million or $5.07 per share in the fourth quarter ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal ...